Tanvex BioPharma - Public Comps and Valuation Multiples

Tanvex BioPharma Overview

About Tanvex BioPharma

Tanvex BioPharma Inc is a biopharmaceutical company. It is engaged in the research, development, manufacture, and sale of biosimilar products and contract development and manufacturing of biological medicine. The company's products are used to cure diseases such as Neutropenia, Breast Cancer, Metastatic Colorectal Cancer, and others. Geographically, the company generates a majority of its revenue from USA, also operates in Taiwan too.

Founded

2013

HQ

Employees

133

Website

tanvex.com

Sectors

Biopharmaceuticals
Contract Research & Manufacturing
BioTech

Financials

LTM Revenue $13.6M

Last FY EBITDA -$33.0M

EV

$447M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Tanvex BioPharma Financials

As of December 2025, Tanvex BioPharma reported last 12-month revenue of $13.6M.

In the same period, Tanvex BioPharma generated -$9.4M in LTM gross profit and -$40.7M in net income.

See Tanvex BioPharma valuation multiples based on analyst estimates

Tanvex BioPharma P&L

In the most recent fiscal year, Tanvex BioPharma reported revenue of $1.1M and EBITDA of -$33.0M.

Tanvex BioPharma expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Tanvex BioPharma valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue	$13.6M	XXX	$1.1M	XXX	XXX	XXX
Gross Profit	-$9.4M	XXX	$0.3M	XXX	XXX	XXX
Gross Margin	-69%	XXX	24%	XXX	XXX	XXX
EBITDA	n/a	XXX	-$33.0M	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	-2996%	XXX	XXX	XXX
EBIT	-$38.7M	XXX	-$43.1M	XXX	XXX	XXX
EBIT Margin	-285%	XXX	-3912%	XXX	XXX	XXX
Net Profit	-$40.7M	XXX	-$43.9M	XXX	XXX	XXX
Net Margin	-299%	XXX	-3984%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Tanvex BioPharma including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $13.6M. In the most recent fiscal year, Tanvex BioPharma achieved $1.1M in revenue and -$33.0M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2026)	Next Fiscal Year (2027)	Two Years Forward (2028)
Total Revenue	$13.6M	Analyst estimates available to subscribers	$1.1M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	-$9.4M	Analyst estimates available to subscribers	$0.3M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	-69.4% gross margin	Analyst estimates available to subscribers	23.9% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	n/a	Analyst estimates available to subscribers	-$33.0M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	n/a	Analyst estimates available to subscribers	-2995.6% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	-$38.7M	Analyst estimates available to subscribers	-$43.1M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	-284.8% EBIT margin	Analyst estimates available to subscribers	-3912.4% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	-$40.7M	Analyst estimates available to subscribers	-$43.9M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	-299.4% net profit margin	Analyst estimates available to subscribers	-3983.9% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Tanvex BioPharma

This financial data table provides comprehensive performance metrics for Tanvex BioPharma, a company based in Taiwan. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Tanvex BioPharma generated $13.6M in revenue over the last twelve months.
Gross profit for the last twelve months was -$9.4M.
Net income over the last twelve months reached -$40.7M.

Fiscal Year Performance

In the most recent fiscal year, Tanvex BioPharma reported $1.1M in total revenue.
Fiscal year EBITDA was -$33.0M.
The company maintained a gross profit margin of 23.9% in the most recent fiscal year.
EBITDA margin for the fiscal year was -2995.6%.
Net profit margin reached -3983.9% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Tanvex BioPharma. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Tanvex BioPharma Stock Performance

Tanvex BioPharma has current market cap of TWD 13.9B (or $442M), and EV of TWD 14.1B (or $447M).

Market Cap Evolution

Tanvex BioPharma Stock Data

As of January 16, 2026, Tanvex BioPharma's stock price is TWD 52 (or $2).

See Tanvex BioPharma trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$447M	$442M	XXX	XXX	XXX	XXX	$-0.20

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Tanvex BioPharma Valuation Multiples

Tanvex BioPharma's trades at 32.9x EV/Revenue multiple, and -13.5x EV/EBITDA.

See valuation multiples for Tanvex BioPharma and 15K+ public comps

Tanvex BioPharma Financial Valuation Multiples

As of January 16, 2026, Tanvex BioPharma has market cap of $442M and EV of $447M.

Equity research analysts estimate Tanvex BioPharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Tanvex BioPharma has a P/E ratio of -10.9x.

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Market cap (current)	$442M	XXX	$442M	XXX	XXX	XXX
EV (current)	$447M	XXX	$447M	XXX	XXX	XXX
EV/Revenue	32.9x	XXX	32.9x	XXX	XXX	XXX
EV/EBITDA	n/a	XXX	-13.5x	XXX	XXX	XXX
EV/EBIT	-11.5x	XXX	-11.5x	XXX	XXX	XXX
EV/Gross Profit	-47.4x	XXX	n/a	XXX	XXX	XXX
P/E	-10.9x	XXX	-10.9x	XXX	XXX	XXX
EV/FCF	-10.0x	XXX	-10.0x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Tanvex BioPharma Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Tanvex BioPharma Margins & Growth Rates

Tanvex BioPharma's last 12 month revenue growth is 183%

Tanvex BioPharma's revenue per employee in the last FY averaged $8K, while opex per employee averaged $0.3M for the same period.

Tanvex BioPharma's rule of 40 is -2674% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Tanvex BioPharma's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Tanvex BioPharma and other 15K+ public comps

Tanvex BioPharma Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue Growth	183%	XXX	n/a	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Growth	n/a	XXX	n/a	XXX	XXX	XXX
Rule of 40	-2674%	XXX	n/a	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	n/a	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$8K	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.3M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	129%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	3052%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	3936%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial